The Association of Higher Plasma Macrophage Migration Inhibitory Factor Levels with Lower Bone Mineral Density and Higher Bone Turnover Rate in Postmenopausal Women.
10.3803/EnM.2016.31.3.454
- Author:
Hyeonmok KIM
1
;
Seong Hee AHN
;
Chaeho SHIN
;
Seung Hun LEE
;
Beom Jun KIM
;
Jung Min KOH
Author Information
1. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. umkbj0825@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Macrophage migration-inhibitory factors;
Bone density;
Bone remodeling;
Bone strength;
Osteoporosis
- MeSH:
Animals;
Bone Density*;
Bone Remodeling*;
Confounding Factors (Epidemiology);
Cross-Sectional Studies;
Female;
Femur;
Femur Neck;
Humans;
Macrophage Migration-Inhibitory Factors;
Macrophages*;
Metabolism;
Odds Ratio;
Osteoporosis;
Phenotype;
Plasma*;
Prevalence;
Spine;
World Health Organization
- From:Endocrinology and Metabolism
2016;31(3):454-461
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Despite evidence from animal and clinical studies showing the detrimental effects of macrophage migration inhibitory factor (MIF) on bone metabolism, there are no clinical studies relating circulating MIF levels to osteoporosis-related phenotypes. This cross-sectional study investigated the association of plasma MIF with bone mineral density (BMD), bone turnover markers (BTMs), and prevalence of osteoporosis in postmenopausal Korean women. METHODS: A total of 246 women not taking any medications or diagnosed with any diseases that could affect bone metabolism were enrolled. BMD values at the lumbar spine, femoral neck, and total femur, and blood levels of MIF and BTMs were measured in all subjects. Osteoporosis was defined by World Health Organization criteria. RESULTS: Before and after adjustment for confounding variables, higher MIF levels were significantly associated with lower BMD values at all measured sites and higher levels of all BTMs. All BMD values and BTMs significantly changed in a dose-dependent fashion across increasing MIF quartile. When participants were divided into two groups according to osteoporosis status, postmenopausal women with osteoporosis demonstrated 24.2% higher plasma MIF levels than those without osteoporosis (P=0.041). The odds ratio per each standard deviation increment of MIF levels for prevalent osteoporosis was 1.32 (95% confidence interval, 1.01 to 1.73). CONCLUSION: This study provides the first epidemiological evidence that higher plasma MIF may be associated with higher risk of osteoporosis resulting from lower bone mass and higher bone turnover rate, and thus it could be a potential biomarker of poor bone health outcomes in postmenopausal women.
